LONGEVITY & CELLULAR HEALTH / COLOPHON
About This Research Digest
An independent, citation-grounded literature digest on two molecules at the cellular edge of aging research. Not a vendor. Not a clinic. Not medical advice.
What AgeDefy Peptides is
AgeDefy Peptides is an independent editorial reference covering the published research on two molecules studied in cellular aging and healthspan: NAD+ and MOTS-c, with MOTS-c as the lead compound. The site exists because this literature is simultaneously important and frequently oversimplified — consumer claims about longevity, performance, and fat loss often run far ahead of what the peer-reviewed record actually supports, and the actual record — trials with real results, mechanisms with real caveats — tends to get buried under marketing language.
The organizing idea is the cellular-energetics angle: two molecules that approach aging at the level of metabolism and mitochondrial function, one a coenzyme whose decline with age is well documented, the other a newly discovered retrograde signal from the mitochondria themselves. Each has its own page; a comparison page lines them up directly; and a single shared references list aggregates every cited source.
How it is compiled
Three principles govern what appears on this site.
Everything is anchored to the peer-reviewed literature. Every research claim is tied to a numbered citation — PubMed-indexed journal articles and reviews, with DOIs or PubMed links — collected on the references page. Where a finding comes from a review article rather than a primary study, the review is cited as such.
The evidence is reported at its actual strength. Doses and outcomes are described in the organism and route in which they were studied — for example, "in aged mice given MOTS-c subcutaneously" — never scaled to humans or framed as a recommendation. Where evidence is preclinical, rests on a surrogate endpoint rather than a clinical outcome, or comes from a single study, the page says so. That precision about what evidence is and is not is the point of this desk.
The two pages are cross-referenced. Because NAD+ and MOTS-c share mechanistic territory — both touch AMPK signaling; MOTS-c's folate-cycle inhibition has direct implications for cellular energy balance — the pages link to each other so the mechanistic resonances are visible.
What it is not
AgeDefy Peptides is not a store, not a clinic, and not a source of medical advice. It does not sell, supply, source, or broker any compound, supplement, or research chemical, and it has no affiliate or referral relationship with any vendor. It does not employ clinicians, diagnose any condition, or prescribe anything. It does not recommend a dose, schedule, or route of administration for any person, and it never converts an animal-study dose into a human recommendation.
The molecules discussed here occupy different regulatory categories — NAD+ precursors are dietary supplements with contested regulatory standing, while MOTS-c is a research chemical prohibited in sport — but neither is a straightforward approved medicine. Readers interested in any condition described in the underlying research should consult a licensed clinician in their own jurisdiction, working with regulated, evidence-based options. This site offers a calm, accurate map of the literature — nothing more.